Overview
- The Institutional Program published in the federal gazette sets a state strategy to rebuild vaccine and medicine production and fix chronic supply failures rooted in procurement and logistics weaknesses.
- Birmex lays out annual targets to raise public-sector coverage to 90% in 2025, 92% in 2026, 95% in 2027, 97% in 2028 and 100% starting in 2029.
- Planned actions include modernizing plants, expanding research and technology transfer, deploying integrated logistics and last‑mile delivery, and strengthening quality management aligned with COFEPRIS and WHO standards.
- The company acknowledges past operational and distribution deficiencies and says achieving full, on‑time supply will require a deep institutional transformation.
- Health official Eduardo Clark has launched a procurement process for IMSS, ISSSTE and IMSS‑Bienestar for 2027–2028 with Birmex handling distribution and purchases limited to certified laboratories to curb corruption and counterfeit risks, a shift drawing resistance from distributors.